United Therapeutics Stock Rises 12.6% to $588.65
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy UTHR?
United Therapeutics is up 12.6%, or $65.82 to $588.65.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to fall
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 588.360
Low
423.00
Averages
534.50
High
645.00
Current: 588.360
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Therapeutics Shares Surge 12.7% After Positive Study Results
- Clinical Trial Success: United Therapeutics announced that its TETON-1 pivotal study demonstrated that nebulized Tyvaso significantly improved lung function in idiopathic pulmonary fibrosis patients, with a 130.1 mL increase in forced vital capacity (FVC) over 52 weeks, greatly enhancing patient quality of life.
- Safety Profile Maintained: The positive results were consistent across all patient subgroups, with no new safety concerns identified, which further strengthens market confidence in Tyvaso and may drive future sales growth.
- Strong Stock Reaction: Following this news, United Therapeutics shares surged 12.7% in afternoon trading, indicating strong market recognition of the company's potential, especially given that there have only been 9 moves greater than 5% in the past year, highlighting the significance of this announcement.
- Analyst Outlook Positive: UBS raised its price target for United Therapeutics from $385 to $415 while maintaining a 'Buy' rating, reflecting confidence in the potential of Tyvaso and suggesting further upward momentum for the stock.
See More
UNITED THERAPEUTICS STOCK SOARS 14.71% FOLLOWING SUCCESSFUL LATE-STAGE STUDY OF INHALED DRUG TYVASO FOR IDIOPATHIC PULMONARY FIBROSIS
- Stock Performance: United Therapeutics shares increased by 14.71% following positive news regarding its inhaled drug, Tyvaso.
- Study Focus: The drug's main goal is to treat patients with idiopathic pulmonary arterial hypertension in a late-stage study.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
US Stock Market Declines Amid Rising Oil Prices
- Oil Price Surge Impacts Markets: The S&P 500 Index fell by 0.75%, the Dow Jones Industrial Average by 0.21%, and the Nasdaq 100 by 1.18% as the market reacts to the first oil settlement exceeding $100 since 2022, highlighting concerns over rising energy costs amid ongoing supply chain risks.
- Uncertain Fed Policy Outlook: Federal Reserve Chair Jerome Powell noted that while the central bank is monitoring the surge in energy prices, its tools to address supply-side shocks are limited, with markets pricing in only a 3% chance of a 25 bp rate hike at the April meeting, indicating investor uncertainty about future monetary policy.
- Escalating Middle East Tensions: US and Israeli forces continue military operations in Iran, with the Pentagon preparing for weeks of ground operations as approximately 3,500 sailors and Marines arrive in the region, potentially exacerbating global energy supply issues.
- Positive Bond Market Reaction: The 10-year Treasury yield fell to 4.330% as speculation grows that the ongoing conflict in the Middle East may lead to fuel shortages, offsetting inflation fears and supporting Treasury prices amid declining inflation expectations.
See More
Mixed U.S. Stock Indices Amid Rising Oil Prices
- Mixed Stock Performance: The S&P 500 Index fell by 0.29%, while the Dow Jones Industrial Average rose by 0.26%, and the Nasdaq 100 Index decreased by 0.67%, indicating a complex market reaction to Federal Reserve policies and international tensions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to disruptions in oil and gas flows through the Strait of Hormuz caused by the Iran conflict, which could negatively impact global economic growth.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity index dropped from -0.4 to -0.2, falling short of the expected increase to 2.0, suggesting challenges in economic recovery that may influence future policy decisions.
- Escalating International Tensions: U.S. and Israeli military actions against Iran have intensified, with 3,500 sailors and Marines deployed to the Middle East, potentially leading to further volatility in energy markets and impacting global supply chains.
See More
US Stocks Rise as Oil Prices Hit Three-Week High
- Market Gains: The S&P 500 Index rose by 0.58%, the Dow Jones Industrial Average increased by 0.91%, and the Nasdaq 100 Index climbed by 0.30%, reflecting a positive market sentiment amid expectations that the Fed may keep interest rates unchanged.
- Declining Bond Yields: The 10-year Treasury note yield fell by 10 basis points to 4.33%, driven by concerns that the ongoing war in the Middle East could lead to a fuel shortage, potentially hindering global economic growth and influencing the Fed's future rate decisions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to Iranian attacks on shipping, raising fears that the closure of the Strait of Hormuz could disrupt global oil and gas supplies, which may lead to significant price increases.
- Manufacturing Activity Decline: The Dallas Fed's manufacturing activity survey dropped by 0.4 to -0.2, falling short of the expected increase to 2.0, indicating signs of economic slowdown that could impact future investment decisions.
See More
United Therapeutics Shares Surge 12.7% After Positive Study Results
- Clinical Trial Success: United Therapeutics announced that its TETON-1 pivotal study demonstrated that nebulized Tyvaso significantly improved lung function in idiopathic pulmonary fibrosis patients, with a 130.1 mL increase in forced vital capacity (FVC) over 52 weeks, greatly enhancing patient quality of life.
- Safety Profile Maintained: The positive results were consistent across all patient subgroups, with no new safety concerns identified, which further strengthens market confidence in Tyvaso and may drive future sales growth.
- Strong Stock Reaction: Following this news, United Therapeutics shares surged 12.7% in afternoon trading, indicating strong market recognition of the company's potential, especially given that there have only been 9 moves greater than 5% in the past year, highlighting the significance of this announcement.
- Analyst Outlook Positive: UBS raised its price target for United Therapeutics from $385 to $415 while maintaining a 'Buy' rating, reflecting confidence in the potential of Tyvaso and suggesting further upward momentum for the stock.
See More
UNITED THERAPEUTICS STOCK SOARS 14.71% FOLLOWING SUCCESSFUL LATE-STAGE STUDY OF INHALED DRUG TYVASO FOR IDIOPATHIC PULMONARY FIBROSIS
- Stock Performance: United Therapeutics shares increased by 14.71% following positive news regarding its inhaled drug, Tyvaso.
- Study Focus: The drug's main goal is to treat patients with idiopathic pulmonary arterial hypertension in a late-stage study.
See More
Mixed Close for US Stocks as Nasdaq Hits 7.75-Month Low Amid Middle East Tensions
- Divergent Market Performance: On Monday, the S&P 500 index fell by 0.39%, while the Nasdaq 100 hit a 7.75-month low, indicating market concerns over the Middle East situation, particularly exacerbated by a sell-off in chip stocks, which negatively impacted investor confidence.
- Declining Bond Yields: The 10-year T-note yield dropped by 8 basis points to 4.34%, reflecting market fears that the ongoing war in the Middle East could lead to fuel shortages, potentially suppressing expectations for Fed rate hikes and highlighting economic growth uncertainties.
- Rising Crude Oil Prices: Crude oil prices surged over 3% to a three-week high due to Iranian attacks on the Strait of Hormuz, indicating severe threats to global energy supply chains, which could lead to soaring prices in the future and impact the global economy.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity survey fell to -0.2, below the expected 2.0, reflecting signs of economic slowdown that could influence corporate investment decisions and future economic growth.
See More
US Stock Market Declines Amid Rising Oil Prices
- Oil Price Surge Impacts Markets: The S&P 500 Index fell by 0.75%, the Dow Jones Industrial Average by 0.21%, and the Nasdaq 100 by 1.18% as the market reacts to the first oil settlement exceeding $100 since 2022, highlighting concerns over rising energy costs amid ongoing supply chain risks.
- Uncertain Fed Policy Outlook: Federal Reserve Chair Jerome Powell noted that while the central bank is monitoring the surge in energy prices, its tools to address supply-side shocks are limited, with markets pricing in only a 3% chance of a 25 bp rate hike at the April meeting, indicating investor uncertainty about future monetary policy.
- Escalating Middle East Tensions: US and Israeli forces continue military operations in Iran, with the Pentagon preparing for weeks of ground operations as approximately 3,500 sailors and Marines arrive in the region, potentially exacerbating global energy supply issues.
- Positive Bond Market Reaction: The 10-year Treasury yield fell to 4.330% as speculation grows that the ongoing conflict in the Middle East may lead to fuel shortages, offsetting inflation fears and supporting Treasury prices amid declining inflation expectations.
See More
Mixed U.S. Stock Indices Amid Rising Oil Prices
- Mixed Stock Performance: The S&P 500 Index fell by 0.29%, while the Dow Jones Industrial Average rose by 0.26%, and the Nasdaq 100 Index decreased by 0.67%, indicating a complex market reaction to Federal Reserve policies and international tensions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to disruptions in oil and gas flows through the Strait of Hormuz caused by the Iran conflict, which could negatively impact global economic growth.
- Weak Manufacturing Activity: The Dallas Fed manufacturing activity index dropped from -0.4 to -0.2, falling short of the expected increase to 2.0, suggesting challenges in economic recovery that may influence future policy decisions.
- Escalating International Tensions: U.S. and Israeli military actions against Iran have intensified, with 3,500 sailors and Marines deployed to the Middle East, potentially leading to further volatility in energy markets and impacting global supply chains.
See More
US Stocks Rise as Oil Prices Hit Three-Week High
- Market Gains: The S&P 500 Index rose by 0.58%, the Dow Jones Industrial Average increased by 0.91%, and the Nasdaq 100 Index climbed by 0.30%, reflecting a positive market sentiment amid expectations that the Fed may keep interest rates unchanged.
- Declining Bond Yields: The 10-year Treasury note yield fell by 10 basis points to 4.33%, driven by concerns that the ongoing war in the Middle East could lead to a fuel shortage, potentially hindering global economic growth and influencing the Fed's future rate decisions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to Iranian attacks on shipping, raising fears that the closure of the Strait of Hormuz could disrupt global oil and gas supplies, which may lead to significant price increases.
- Manufacturing Activity Decline: The Dallas Fed's manufacturing activity survey dropped by 0.4 to -0.2, falling short of the expected increase to 2.0, indicating signs of economic slowdown that could impact future investment decisions.
See More
